Category: 3. Business

  • Cloudy with a chance of soot: The role of fuel composition in aviation’s non-CO2 impact

    Cloudy with a chance of soot: The role of fuel composition in aviation’s non-CO2 impact

    Jet fuel can be produced from several different sources, including fossil fuels, feedstocks of biological origin, and captured carbon. Depending on the feedstock used, the lifecycle carbon dioxide (CO2) emissions of the fuel can vary widely. Robust sustainability criteria prioritizing minimal life-cycle carbon intensity can help to ensure that sustainable aviation fuels (SAFs) are truly low carbon, which is crucial to achieving aviation’s 2050 net-zero target.

    Unlike CO2 emissions, the non-CO2 emissions associated with combusting aviation fuels are not dependent on the feedstock of the fuel, but rather its composition. Specifically, fuel composition plays a key role in determining the particulate matter (PM) emissions and contrail impact of combustion within a given aircraft engine. We’ll start by understanding how these are related.

    Regardless of the feedstock used to produce it, jet fuel can be engineered with varying levels of specific types of hydrocarbons (such as aromatics and naphthalenes), as long as the resulting fuel meets relevant standards set by ASTM International—an organization that sets technical standards for a range of industries. ASTM has separate standards for conventional fossil jet fuel and SAF.

    Conventional fossil jet fuel, which makes up nearly all aviation fuel used today, typically has a fuel hydrogen content of about 13.8%. Fuel hydrogen content has been found to be the best correlating parameter when assessing the relationship between fuel composition and non-volatile particulate matter (nvPM) emissions, or soot. These ultrafine particulates can be measured at the aircraft engine exit in the solid phase, typically under 100 nm in diameter. On the other hand, volatile particulate matter (vPM) does not exist at the engine exit and forms in the exhaust plume, where it later condenses into particles. vPM formation in aircraft has been tied to compounds such as sulphates in fuels and vented engine lubrication oil.

    SAF tends to have a higher hydrogen content than typical fossil jet fuel and little to no aromatics and sulfur, which translates into fewer PM emissions. Modeling results from a 2022 study by Teoh et al. estimated that fleetwide adoption of 100% SAF in the North Atlantic would result in 52% lower nvPM emissions. Likewise, experimental results from the 2024 ECLIF3 project, the first in-flight test campaign running on 100% SAF, measured a 35% reduction in nvPM particles.

    Now for how this relates to contrails. This is a bit more complicated, because contrail formation is dependent on both engine emissions and meteorological conditions. While there is uncertainty about the climate impact of individual contrails, there is agreement that collectively, they have a net warming impact. The ideal meteorological conditions for persistent contrail formation include hot engine exhaust, cold temperatures, and high humidity. Areas where the meteorological conditions are conducive to contrails are called ice supersaturated regions, or ISSRs. When an aircraft is flying through an ISSR, ice crystals can nucleate around particulate matter at the engine exit and emissions plume, spreading to form contrails.

    Recent modeling and flight tests indicate that nvPM reductions from SAF use can enable reductions in persistent contrail formation in rich-burn engines, which make up most of the existing fleet. The modeling results from Teoh et al. noted above estimated a 44% reduction in contrail radiative forcing resulting from the modeled decrease in nvPM emissions; climate modeling using the ECLIF3 experimental results showed a 26% reduction.

    Although further flight testing is needed to rigorously quantify this relationship for different engines, there is a clear, observed trend of reduced contrail radiative forcing in rich-burn engines resulting from SAF use. When weighing the benefits of SAF relative to conventional fossil jet fuel, the impact of SAF thus widens considerably if you include the additional air quality and climate benefits coming from reduced PM emissions and contrail formation.

    Importantly, the ability of SAF to contribute to non-CO2 emissions reductions will be limited by its penetration into the aviation fuel supply. In 2024, SAF made up only about 0.3% of global jet fuel use; even in the most ambitious existing SAF mandate, which took effect in the United Kingdom this year, SAF blends reach 10% in 2030. Uniform blending of SAF at low percentages greatly dilutes any non-CO2 emissions benefits. In this context, avoidance may be a more cost-effective and accessible solution to address contrails in the near term.

    Meanwhile, to maximize the potential non-CO2 emissions reductions from fuel composition, airlines could explore the feasibility of hydroprocessing fossil jet fuel until SAF is widely available. Hydroprocessing includes refinery processes, such as hydrotreatment and hydrocracking, that add hydrogen to a fuel at high temperatures and pressures, greatly reducing aromatic and sulfur content and, consequently, PM emissions. When considering this option, non-CO2 climate and air quality benefits should be weighed against potential tradeoffs at refineries coming from the required energy input for these processes. However, initial studies indicate that the overall climate benefit of using hydroprocessed jet fuel could outweigh penalties from additional refinery emissions and serve as a promising near-term mitigation strategy as SAF production grows in parallel.

    It is clear that the chemical properties of jet fuel play a key role in aviation’s non-CO2 impact. As the aviation sector works to mitigate its climate impact, policymakers could consider targeted use of low-carbon SAF on contrail-prone routes and using hydroprocessed fossil jet fuel to unlock near-term climate benefits and improved local air quality.

    Continue Reading

  • Big AI’s reliance on circular deals is raising fears of a bubble

    Big AI’s reliance on circular deals is raising fears of a bubble

    Nvidia CEO Jensen Huang has characterized his company’s $100 billion OpenAI investment as an opportunity to invest in the next “multitrillion-dollar” company.

    Nvidia itself is part of that club, with a market valuation of $4.5 trillion.

    Investments like Nvidia’s in OpenAI are predicated on “the confidence in the revenues” a company can sustain, Huang said on the “BG2” technology podcast.

    Nvidia and OpenAI already have an indirect collaboration, through the cloud-computing darling CoreWeave, based in New Jersey, which has a standing agreement with OpenAI to sell Nvidia systems to OpenAI.

    One of CoreWeave’s biggest investors? Nvidia.

    There are other players in the thicket. Oracle has said it will spend about $40 billion on Nvidia’s chips to power one of OpenAI’s data centers.

    Oracle and OpenAI are also collaborating with Japan’s SoftBank group on plans to spend $500 billion on additional data centers in a project known as Stargate.

    Nvidia is a “core technology partner” to the Stargate deal. SoftBank owns a $3 billion stake in Nvidia.

    An OpenAI representative referred NBC News to CFO Sarah Friar’s recent comments to CNBC, in which she discussed the company’s need for additional computing power. But she did not directly address the “circular” question.

    Nvidia and CoreWeave declined to comment. Representatives for Oracle and SoftBank did not respond to requests for comment.

    To some investment advisers, the Nvidia-OpenAI deal is especially reminiscent of the ones announced in the lead-up to the 2000 dot-com bubble burst.

    In March of that year, the tech-heavy Nasdaq Composite stock index fell by 77% and wiped out billions of dollars in market value.

    It would take 15 more years before the Nasdaq returned to its March 2000 highs.

    “There’s a healthy part and an unhealthy part” to the AI ecosystem, said Gil Luria, a managing director at D.A. Davidson financial group who covers technology.

    The unhealthy part has become marked by “related-party transactions” like the ones involving these companies, he said, which can artificially prop up the value of the firms involved.

    If investors decide the ties among the AI giants are getting too close, he said, “there will be some deflating activity.” That’s Wall Street-speak for a bubble’s bursting.

    Altman recently sought to calm fears of a looming AI bust, suggesting that it was part of the life cycle of every industry.

    “Between the ten years we’ve already been operating and the many decades ahead of us, there will be booms and busts,” Altman said last month during a tour of the massive data center complex that OpenAI is building in Abilene, Texas.

    “People will over-invest and lose money, and underinvest and lose a lot of revenue,” he said.

    Concerns about AI’s insular web of deals and investments have been outweighed by the near-term potential for nearly unimaginable returns.

    Rather than worry about whether AI is really growing at the pace it appears to be, many investors are instead focused on whether the companies can grow fast enough and make enough profit to justify the mammoth investments being poured into them.

    “For this whole massive experiment to work without causing large losses, [OpenAI] and its peers now have got to generate huge revenues and profits to pay for all the obligations they are signing up for and at the same time provide a return to its investors,” wrote Peter Boockvar, chief investment officer of OnePoint BFG Wealth Partners and author of The Boock Report.

    As long as tech-firm valuations keep soaring into the stratosphere and investors keep getting rich, the incentives remain for Wall Street to bless the boom and ignore the doomsday scenarios.

    As of Wednesday, more than 35% of the market value of all the companies in the S&P 500 Index — more than $20 trillion — came from just seven tech companies, collectively known on Wall Street as the “Magnificent 7.”

    And each of them — Apple, Google parent Alphabet, Amazon, Facebook parent Meta, Microsoft, Nvidia and Tesla — is heavily involved in AI projects.

    Continue Reading

  • Asian Stocks Poised to Track Tech-Fueled US Gains: Markets Wrap

    Asian Stocks Poised to Track Tech-Fueled US Gains: Markets Wrap

    (Bloomberg) — Stocks in Asia look set for a positive open after Advanced Micro Devices Inc.’s blockbuster deal with OpenAI helped fuel a rally in chipmakers that sent US shares to all-time highs. The dollar rose, while the yen held its biggest drop in almost five months.

    Equity futures indicated gains in Tokyo, Hong Kong and Sydney. The S&P 500 climbed for a seventh session — the longest advance since May — after AMD soared 24% following the deal to build artificial intelligence infrastructure. In Asia, options traders are the least bullish on the yen in more than three years after pro-stimulus lawmaker Sanae Takaichi’s near-certain ascent to become the next prime minister.

    Monday’s AMD deal is the latest big-budget data center agreement this year. It follows last month’s announcement that Nvidia was planning to invest as much as $100 billion in OpenAI amid demand for tools like ChatGPT and the computing power needed to make them run.

    “Semiconductors are ‘on fire’,” said Louis Navellier at Navellier & Associates. “The AI narrative continues to gain momentum.”

    With “animal spirits” surrounding the AI phenomenon getting yet another boost, Matt Maley at Miller Tabak notes it’s no surprise that issues like the US government shutdown are being mostly ignored by traders.

    Long-term Treasuries underperformed, joining a similar trend through much of Europe and Asia amid fiscal concerns. Australia’s 10-year yield climbed five basis points early Tuesday.

    Gold extended gains in early Asia trading to near $4,000 an ounce. Oil held Monday’s gain after dropping last week, as a modest production increase by OPEC+ over the weekend staved off traders’ fears of a super-sized hike.

    Japanese stocks surged on Monday, with the Nikkei 225 Stock Average closing 4.8% higher at a fresh record amid hopes of more fiscal spending amid Takaichi’s win. The yen lost 1.8% against the dollar to past 150 and sank to an all-time low against the euro, while longer-term bonds fell on concern her policies will require more government spending and fan inflation.

    In the US, companies are set to enjoy a better-than-expected earnings season as a robust economy and a solid outlook for AI have left estimates looking too low, according to Goldman Sachs Group Inc. strategists led by David Kostin. They also expect the so-called Magnificent Seven group of tech heavyweights to beat expectations.

    At Ritholtz Wealth Management, Callie Cox says markets feel “untouchable,” which is why there are so many people talking about valuations.

    “Higher valuations aren’t unusual, but earnings need to grab the baton for the rally to continue,” she said. “Ideally, we want to see profits support prices.”

    To Anthony Saglimbene at Ameriprise, it’s possible that some level of investment in the AI buildout today may not yield the degree of return investors hope for, and valuations among some of the leaders would likely need to be adjusted downward.

    “However, given the size and scale of companies and industries that have yet to tap into AI in a meaningful way, we are less concerned that we are on the cusp of a dot-com bubble just yet,” he said.

    Some of the main moves in markets:

    Stocks

    Hang Seng futures rose 0.6% as of 7:19 a.m. Tokyo time S&P/ASX 200 futures rose 0.1% Nikkei 225 futures rose 0.8% S&P 500 futures were little changed Currencies

    The Bloomberg Dollar Spot Index rose 0.3% Cryptocurrencies

    Bitcoin was little changed at $125,284.64 Ether rose 0.2% to $4,699.27 Bonds

    The yield on 10-year Treasuries advanced three basis points to 4.15% Australia’s 10-year yield climbed five basis points to 4.38% Commodities

    Spot gold rose 0.3% to $3,971.98 an ounce West Texas Intermediate crude rose 0.1% to $61.75 a barrel This story was produced with the assistance of Bloomberg Automation.

    ©2025 Bloomberg L.P.

    Continue Reading

  • Bombardier Completes Redemption for All of its 7.125% Senior Notes due 2026 and Partial Redemption for US$83,711,000 of its 7.875% Senior Notes due 2027

    Bombardier Completes Redemption for All of its 7.125% Senior Notes due 2026 and Partial Redemption for US$83,711,000 of its 7.875% Senior Notes due 2027

    Bombardier Inc. (“Bombardier”) today announced that it has redeemed all remaining outstanding US$166,289,000 aggregate principal amount of its 7.125% Senior Notes due 2026 (the “2026 Notes”) and US$83,711,000 aggregate principal amount of its outstanding 7.875% Senior Notes due 2027 (together with the 2026 Notes, the “Redemption Notes”), in each case effective October 4, 2025 and as set forth in the respective notices of redemption issued September 4, 2025.  

    Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. 

    This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful.  

    The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. The securities mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada may only be made on a basis which is exempt from the prospectus requirements of such securities laws.  

    FORWARD-LOOKING STATEMENTS 

    Certain statements in this announcement are forward-looking statements based on current expectations. By their nature, forward-looking statements require us to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from those set forth in the forward-looking statements. 

    For information 

    Francis Richer de La Flèche 

    Vice President, Financial Planning and Investor Relations 
    Bombardier 
    +1 514 240 9649 

    Mark Masluch 

    Senior Director, Communications 
    Bombardier 
    +1 514 855 7167 

     

    Continue Reading

  • New Zealand Q3 business confidence worsens, think tank says – Reuters

    1. New Zealand Q3 business confidence worsens, think tank says  Reuters
    2. New Zealand Q3 business confidence 18% vs 22% previous quarter  investingLive
    3. No sign of respite for struggling economy  National Business Review
    4. NZIER releases bleak business survey on eve of Reserve Bank OCR call  ThePost.co.nz
    5. New Zealand Firms’ Gloomy Outlook Raises Risk of Recession  Bloomberg.com

    Continue Reading

  • New Zealand central bank to set up new financial policy committee

    New Zealand central bank to set up new financial policy committee

    WELLINGTON, Oct 7 (Reuters) – New Zealand’s central bank said on Tuesday it would form a new financial policy committee that would give it the power to set prudential requirements for banks and help it to make decisions over mortgage lending ratios.

    The move is in line with recommendations that followed a recent parliamentary inquiry into banking competition and will strengthen the Reserve Bank of New Zealand’s financial policy-making, the RBNZ said in a statement.

    Sign up here.

    New Zealand’s centre-right government is pushing for more competition in the country’s banking sector, which is dominated by four large Australian-owned banks: Westpac Banking Corp (WBC.AX), opens new tab, ASB Bank, which is part of Commonwealth Bank of Australia (CBA.AX), opens new tab, Bank of New Zealand, which belongs to National Australia Bank (NAB.AX), opens new tab, and Australia and New Zealand Banking Group (ANZ.AX), opens new tab.

    The committee will consist of the RBNZ chair, its governor, three other board members, and up to two members who are not board members or employees of the central bank, the RBNZ said.

    “The creation of the FPC will strengthen financial policy-making at the RBNZ, with greater focus and expertise brought to bear to make sure that the New Zealand financial system remains strong and stable,” Deputy Chair Rodger Finlay said.

    The committee is planned to be operational from early 2026.

    The RBNZ in August proposed an easing of lenders’ capital requirements, after criticism that the regulations reduced availability of funds in the economy and led to extra costs for borrowers.

    Reporting by Lucy Craymer in Wellington and Renju Jose in Sydney; Editing by Edmund Klamann

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • EUR/USD falls on French political shock and shutdown lift Dollar

    EUR/USD falls on French political shock and shutdown lift Dollar

    EUR/USD retreats during the North American session sponsored by political turmoil in France and US Dollar strength, amid the sixth day of government shutdown in the US. The pair trades at 1.1714, down 0.24%.

    Euro weakens toward 1.17 as Lecomu’s resignation and prolonged US fiscal gridlock bolster safe-haven demand for the Greenback

    Market mood remains positive, as portrayed by Wall Street, but the shared currency depreciates on news that the French Prime Minister Sebastien Lecomu submitted his resignation. The lack of news about negotiations regarding the re-opening of the US government leaves traders leaning on economic data from Europe and speeches by central bank officials.

    The US economic docket will feature the University of Michigan (UoM) Consumer Sentiment survey on Friday. This and the tone of discussions between the White House and Democrats, could set the stage to the release of delayed data in the US.

    Recently, US President Donald Trump said that layoffs could be triggered if the Senate vote on the shutdown fails, adds negotiations are ongoing with Democrats.

    The Financial Times reported that the European Commission intends to propose tariffs of 50% on steel imports worldwide above a quota set at 2013 levels.

    Earlier, economic data in the Eurozone revealed that Retail Sales slowed in August on year-over-year figures. At the same time, the Eurozone Sentix index in October improved slightly, compared to September’s excessive pessimism.

    Euro Price This week

    The table below shows the percentage change of Euro (EUR) against listed major currencies this week. Euro was the strongest against the New Zealand Dollar.

    USD EUR GBP JPY CAD AUD NZD CHF
    USD 0.03% 0.03% -0.06% -0.00% -0.00% 0.05% -0.09%
    EUR -0.03% 0.02% -0.05% -0.02% -0.00% 0.04% 0.02%
    GBP -0.03% -0.02% -0.06% -0.04% 0.02% -0.02% -0.01%
    JPY 0.06% 0.05% 0.06% 0.05% 0.06% -0.01% -0.09%
    CAD 0.00% 0.02% 0.04% -0.05% -0.02% 0.00% 0.03%
    AUD 0.00% 0.00% -0.02% -0.06% 0.02% -0.11% -0.03%
    NZD -0.05% -0.04% 0.02% 0.00% -0.01% 0.11% -0.07%
    CHF 0.09% -0.02% 0.00% 0.09% -0.03% 0.03% 0.07%

    The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Euro from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent EUR (base)/USD (quote).

    Daily digest market movers: The Euro hovers around 1.1700

    • As of writing, the Kansas City Fed President Jeffrey Schmid said that the Fed must maintain inflation credibility and that inflation is too high. He added that monetary policy is appropriately calibrated.
    • Eurozone Retail Sales in August rose by 1% YoY down from 2.2% in July yet mostly aligned with estimates of the previous twelve months. On a monthly basis, figures rose as expected 0.1%, up from August’s -0.5% MoM contraction.
    • The Sentix Index in EZ improved from -9.2 to -5.4, better than the expected -8.5
    • Money markets are fully pricing a 25-basis-point Fed cut at the October 29 meeting, with odds standing at 94%, according to Prime Market Terminal’s interest rate probability tool.

    Technical outlook: EUR/USD holds firm waiting for a fresh catalyst

    The EUR/USD remains subdued at around the 1.1700 mark for the sixth consecutive day, capped on the upside by the 20-day Simple Moving Average (SMA) at 1.1745 and on the downside by the 50-day SMA at 1.1683. Nevertheless, it should be noted that for two straight trading days, the pair achieved successive series of lower highs and hit a two-week low of 1.1651.

    For a bullish continuation, the EUR/USD must clear 1.1760 before testing 1.1800. Once cleared the next resistance would be the July 1 high of 1.1830 ahead of testing the yearly peak at 1.1918.

    Contrarily, the EUR/USD first support would be 1.1700, the 50-day SMA and the 100-day SMA at 1.1625.

    Euro FAQs

    The Euro is the currency for the 19 European Union countries that belong to the Eurozone. It is the second most heavily traded currency in the world behind the US Dollar. In 2022, it accounted for 31% of all foreign exchange transactions, with an average daily turnover of over $2.2 trillion a day.
    EUR/USD is the most heavily traded currency pair in the world, accounting for an estimated 30% off all transactions, followed by EUR/JPY (4%), EUR/GBP (3%) and EUR/AUD (2%).

    The European Central Bank (ECB) in Frankfurt, Germany, is the reserve bank for the Eurozone. The ECB sets interest rates and manages monetary policy.
    The ECB’s primary mandate is to maintain price stability, which means either controlling inflation or stimulating growth. Its primary tool is the raising or lowering of interest rates. Relatively high interest rates – or the expectation of higher rates – will usually benefit the Euro and vice versa.
    The ECB Governing Council makes monetary policy decisions at meetings held eight times a year. Decisions are made by heads of the Eurozone national banks and six permanent members, including the President of the ECB, Christine Lagarde.

    Eurozone inflation data, measured by the Harmonized Index of Consumer Prices (HICP), is an important econometric for the Euro. If inflation rises more than expected, especially if above the ECB’s 2% target, it obliges the ECB to raise interest rates to bring it back under control.
    Relatively high interest rates compared to its counterparts will usually benefit the Euro, as it makes the region more attractive as a place for global investors to park their money.

    Data releases gauge the health of the economy and can impact on the Euro. Indicators such as GDP, Manufacturing and Services PMIs, employment, and consumer sentiment surveys can all influence the direction of the single currency.
    A strong economy is good for the Euro. Not only does it attract more foreign investment but it may encourage the ECB to put up interest rates, which will directly strengthen the Euro. Otherwise, if economic data is weak, the Euro is likely to fall.
    Economic data for the four largest economies in the euro area (Germany, France, Italy and Spain) are especially significant, as they account for 75% of the Eurozone’s economy.

    Another significant data release for the Euro is the Trade Balance. This indicator measures the difference between what a country earns from its exports and what it spends on imports over a given period.
    If a country produces highly sought after exports then its currency will gain in value purely from the extra demand created from foreign buyers seeking to purchase these goods. Therefore, a positive net Trade Balance strengthens a currency and vice versa for a negative balance.

    Continue Reading

  • Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

    STOCKHOLM, Oct. 6, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the Leqembi Iqlik autoinjector. It is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months

    Eisai and their partner Biogen have also launched the Leqembi Companion™ program which aims to provide expanded resources that support patients throughout their Leqembi treatment journey, from initiation through maintenance therapy. The program offers resources such as help with understanding insurance coverage and potential out-of-pocket costs and identifying financial support programs, injection education through Nurse Educators either in-person or virtually to provide patients with training on injecting their maintenance dose using the Leqembi Iqlik, an injection tracking tool and more. There is also a Leqembi Companion app to help support patients and care partners along their treatment journey.

    Alzheimer’s disease is a progressive, relentless disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after removal.[1],[2],[3] The data show that amyloid-beta protofibrils and tau tangles play roles in the neurodegeneration process,[4],[5],[6] and Leqembi is the only approved treatment that fights Alzheimer’s disease in two ways – targeting both amyloid plaque and protofibrils[i], which can impact tau downstream. 

    Due to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped,4,5,6 continuing maintenance treatment after the initial 18-month therapy is essential to slow the progression of AD and extend the therapeutic benefits, helping patients maintain who they are for longer.

    The availability of Leqembi Iqlik in the U.S. offers patients and care partners the ability to use the device at home, shortening treatment time, and providing an option to continue treatment without having to worry about visiting an infusion center. The Leqembi Iqlik also has the potential to reduce healthcare resources associated with IV maintenance dosing, such as preparation for infusion and nurse monitoring, while increasing infusion capacity for new eligible patients to begin initiation treatment and streamlining the overall AD treatment pathway.

    Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer’s disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.

    Please see full Prescribing Information for Leqembi in the US, including Boxed WARNING.

    The information was released for public disclosure, through the agency of the contact person below, on October 6, 2025, at 10:35 p.m. CET.

    For further information, please contact: 
    Oskar Bosson, Vice President Communications and Investor Relations
    E-mail[email protected]
    Telephone: +46 70 410 71 80

    About lecanemab (Leqembi®)
    Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

    Lecanemab is approved in 50 countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 8 countries. Leqembi Iqlik™ is approved for subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease in the US. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in China, the U.S. and others, and applications have been filed in 9 countries and regions.

    Since July 2020, Eisai’s Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer’s disease, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer’s disease and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

    About the collaboration between BioArctic and Eisai
    Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.

    About BioArctic AB
    BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

    [1] Leqembi (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc.

    [2] Iwatsubo T, Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, Cohen S. Clarity AD: a phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer’s disease. Presented at: CTAD Conference; November 29-December 2, 2022; San Francisco, CA.

    [3] Hampel H, Hardy J, Blennow K, et al. The amyloid-? pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.

    [4] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z.

    [5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

    [6] Morris JC. Neurology. 1993;43(11):2412-4.

    [i] Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/bioarctic/r/leqembi–iqlik—lecanemab-irmb–maintenance-treatment-launched-in-the-u-s-,c4246336

    The following files are available for download:

    SOURCE BioArctic

    Continue Reading

  • Biomea's diabetes drug shows promise, may work for those responding to GLP-1 – Reuters

    1. Biomea’s diabetes drug shows promise, may work for those responding to GLP-1  Reuters
    2. Icovamenib shows sustained benefits for hard-to-treat diabetes patients  Investing.com
    3. Biomea Fusion Announces Positive Phase II Study Results  TipRanks
    4. Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients  Quiver Quantitative
    5. Biomea Fusion reports 52-week results from Phase II diabetes trial  Investing.com

    Continue Reading

  • Robe River Joint Venture to invest $733 million to extend West Angelas iron ore mine in Western Australia

    PERTH, Australia–(BUSINESS WIRE)–
    Rio Tinto, Mitsui and Nippon Steel will invest $733 million1 (Rio Tinto share $389 million) to develop the West Angelas Sustaining Project, part of the Robe River Joint Venture in Western Australia’s Pilbara region.

    The project, to develop new iron ore deposits in the West Angelas hub, has now received all necessary State and Federal Government approvals.

    The deposits will maintain the West Angelas hub’s total annual production capacity of 35 million tonnes, extending mining activity for years to come.

    Rio Tinto Iron Ore Chief Executive Matthew Holcz said: “The West Angelas Sustaining Project is built on strong and committed partnerships, both with the joint venture members Mitsui and Nippon Steel, as well as the Yinhawangka and Ngarlawangga Peoples.

    “The West Angelas hub has been an integral part of Rio Tinto Iron Ore since 2002. Securing these approvals ensures ongoing investment in the hub as we continue to supply high-quality, reliable iron ore to meet our global customers’ demand now and into the future.”

    Rio Tinto worked closely with the Yinhawangka and Ngarlawangga Peoples to co-design Social Cultural Heritage Management Plans for the West Angelas Sustaining Project to ensure the ongoing protection and management of cultural heritage and the environment.

    The project will leverage existing West Angelas processing infrastructure and includes the construction of new non-process infrastructure precincts and 22-kilometres of haul roads.

    Ore mined at the new deposits will be autonomously trucked to the West Angelas hub, with first ore scheduled for 2027.

    About 600 jobs will be created during construction. Once operational, the project will help sustain a workforce of about 950 full time equivalent roles at the West Angelas hub.

    The West Angelas Sustaining Project is part of Rio Tinto’s tranche of replacement projects that underpin the company’s ongoing commitment to the Pilbara, and which will have combined total capacity of about 130Mtpa2.

    Additionally, work is well progressed on the pre-feasibility study for Rhodes Ridge, one of the world’s largest and highest quality undeveloped iron ore deposits, which is targeting an initial capacity of up to 40Mtpa and first ore by 2030.

    Additional information

    The Robe River Joint Venture comprises Rio Tinto (53 per cent), Mitsui Iron Ore (33 per cent) and Nippon Steel (14 per cent).

    The Joint Venture dates back to 1972, when operations began in the Robe Valley near Pannawonica, followed by an expansion at West Angelas in 2002. It marked its 50th anniversary in 2022.

    Footnotes

    1 All currency figures are in US dollars and on a 100 per cent basis, unless otherwise specified. The capital for the project is already included in the Group’s replacement capital guidance.

    2 Subject to timing of full capacity. The replacement projects include Western Range which, as previously announced, was opened on 6 June 2025, Brockman Syncline 1, as announced on 6 March 2025, Hope Downs 2, as announced on 24 June 2025, West Angelas (this project) and Greater Nammuldi.

    This announcement is authorised for release to the market by Andy Hodges, Rio Tinto’s Group Company Secretary.

    Please direct all enquiries to media.enquiries@riotinto.com

    Media Relations,

    United Kingdom

    Matthew Klar

    M +44 7796 630 637

    David Outhwaite

    M +44 7787 597 493

    Media Relations,

    Australia

    Matt Chambers

    M +61 433 525 739

    Rachel Pupazzoni

    M +61 438 875 469

    Bruce Tobin

    M +61 419 103 454

    Media Relations,

    Canada

    Simon Letendre

    M +1 514 796 4973

    Malika Cherry

    M +1 418 592 7293

    Vanessa Damha

    M +1 514 715 2152

    Media Relations,

    US & Latin America

    Jesse Riseborough

    M +1 202 394 9480

    Investor Relations,

    United Kingdom

    Rachel Arellano

    M: +44 7584 609 644

    David Ovington

    M +44 7920 010 978

    Laura Brooks

    M +44 7826 942 797

    Weiwei Hu

    M +44 7825 907 230

    Investor Relations,

    Australia

    Tom Gallop

    M +61 439 353 948

    Phoebe Lee

    M +61 413 557 780

    Rio Tinto plc

    6 St James’s Square

    London SW1Y 4AD

    United Kingdom

    T +44 20 7781 2000

    Registered in England

    No. 719885

    Rio Tinto Limited

    Level 43, 120 Collins Street

    Melbourne 3000

    Australia

    T +61 3 9283 3333

    Registered in Australia

    ABN 96 004 458 404

    riotinto.com

    Category: General

    Source: Rio Tinto


    Continue Reading